Loading
A phase 1/2 trial of AZD7789 in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer is a phase 1/2 interventional study registered as NCT04931654 by AstraZeneca, with 136 participants enrolled, started 2021-09-28 and due to reach its primary completion in 2024-12-04. Interventions recorded: AZD7789.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/